Biocytogen just stacked two cancer bets in three days. Is its platform strategy starting to compound?
Read More 2 minute read Pharma Industry News ABBV-RGX-314 : REGENXBIO reports positive Phase 2 data on diabetic retinopathy gene therapy candidate REGENXBIO Inc. has disclosed new findings from its Phase II ALTITUDE trial, focusing on ABBV-RGX-314 as a gene… byPallavi MadhirajuNovember 4, 2023